Literature DB >> 18294814

Buprenorphine and methadone maintenance treatment of heroin addicts preserves immune function.

Paola Sacerdote1, Silvia Franchi, Gilberto Gerra, Vincenzo Leccese, Alberto E Panerai, Lorenzo Somaini.   

Abstract

Opiate addiction influences many physiological functions including immune responses. The objective of this study was to investigate the immune system function in heroin addicted patients submitted to methadone or buprenorphine maintenance treatment compared to untreated heroin addicts and healthy controls. Four groups were studied: group A included nine heroin addicted subjects, who were still injecting heroin; groups B and C were composed of 12 patients previously addicted to heroin, being treated with methadone (mean dosage 58+/-12.7 mg/day) or buprenorphine (mean dose 9.3+/-2.3mg/day) since at least 6 months; group D was composed of 15 sex and age matched healthy controls. Lymphoproliferation and peripheral mononuclear cell cultures production of the Th1 cytokines IL-2 and IFN-gamma, the Th2 cytokine IL-4, and of the pro-inflammatory cytokine TNF-alpha were evaluated in all the patients and controls. PHA-lymphoproliferation was lower in untreated heroin addicts than in controls, while it was normal in methadone and buprenorphine treated patients. An altered Th1/Th2 balance, characterized by reduced IL-4, IFN-gamma and TNF-alpha but normal IL-2 levels, was present in untreated heroin addicted subjects, while the Th1/Th2 balance was well conserved in the methadone and buprenorphine groups. These findings suggest that the immune system abnormalities in heroin addicted patients can be restored to almost normal values by controlled treatment with methadone and buprenorphine.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18294814     DOI: 10.1016/j.bbi.2007.12.013

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   7.217


  26 in total

1.  Dissociable role of tumor necrosis factor alpha gene deletion in methamphetamine self-administration and cue-induced relapsing behavior in mice.

Authors:  Yijin Yan; Atsumi Nitta; Takenao Koseki; Kiyofumi Yamada; Toshitaka Nabeshima
Journal:  Psychopharmacology (Berl)       Date:  2011-12-14       Impact factor: 4.530

Review 2.  Opioid pharmaceuticals and addiction: the issues, and research directions seeking solutions.

Authors:  Wendy M Walwyn; Karen A Miotto; Christopher J Evans
Journal:  Drug Alcohol Depend       Date:  2010-02-25       Impact factor: 4.492

3.  A comprehensive approach to addiction medicine as an appropriate response to the HIV epidemic among drug users.

Authors:  Gilberto Gerra
Journal:  J Food Drug Anal       Date:  2013-12       Impact factor: 6.079

Review 4.  Immunosuppressive effects of opioids--clinical relevance.

Authors:  Alexander Brack; Heike L Rittner; Christoph Stein
Journal:  J Neuroimmune Pharmacol       Date:  2011-07-05       Impact factor: 4.147

Review 5.  Buprenorphine for treating cancer pain.

Authors:  Mia Schmidt-Hansen; Nathan Bromham; Mark Taubert; Stephanie Arnold; Jennifer S Hilgart
Journal:  Cochrane Database Syst Rev       Date:  2015-03-31

6.  Differential antinociceptive effects of buprenorphine and methadone in the presence of HIV-gp120.

Authors:  Jonathan Palma; Alan Cowan; Ellen B Geller; Martin W Adler; Khalid Benamar
Journal:  Drug Alcohol Depend       Date:  2011-05-19       Impact factor: 4.492

Review 7.  Buprenorphine for neuropathic pain in adults.

Authors:  Philip J Wiffen; Sheena Derry; R Andrew Moore; Cathy Stannard; Dominic Aldington; Peter Cole; Roger Knaggs
Journal:  Cochrane Database Syst Rev       Date:  2015-09-30

8.  Analgesic efficacy of buprenorphine in the presence of high levels of SDF-1α/CXCL12 in the brain.

Authors:  Khalid Benamar; Jonathan Palma; Alan Cowan; Ellen B Geller; Martin W Adler
Journal:  Drug Alcohol Depend       Date:  2010-11-26       Impact factor: 4.492

9.  Active opioid use does not attenuate the humoral responses to inactivated influenza vaccine.

Authors:  Ekaterina Moroz; Randy A Albrecht; Brandon Aden; Ann Bordwine Beeder; Jianda Yuan; Adolfo García-Sastre; Brian R Edlin; Mirella Salvatore
Journal:  Vaccine       Date:  2016-02-06       Impact factor: 3.641

10.  The impact of prescribed opioids on CD4 cell count recovery among HIV-infected patients newly initiating antiretroviral therapy.

Authors:  E J Edelman; K S Gordon; J P Tate; W C Becker; K Bryant; K Crothers; J R Gaither; C L Gibert; A J Gordon; Bdl Marshall; M C Rodriguez-Barradas; J H Samet; M Skanderson; A C Justice; D A Fiellin
Journal:  HIV Med       Date:  2016-11       Impact factor: 3.180

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.